NEWS

WWFH recently partnered with Life Sciences Pennsylvania (LSPA) and the Council for Innovation Promotion (C4IP) to convene a roundtable with Rep. Madeleine Dean and leaders from across the life sciences sector at Rockland Immunochemicals, just outside the Philadelphia area. Pennsylvania plays a critical role in the nation’s innovation economy – supporting more than 262,350 jobs, including 56,086 direct roles, and generated approximately $85.2 billion in economic output in 20

On June 9, We Work For Health hosted a webinar convening leaders across business, venture capital, legal and innovation sectors to examine how drug pricing proposals – such as Most Favored Nation policies – could impact U.S. biomedical innovation, investment and future patient access to medicines. Panelists emphasized that U.S. biomedical innovation depends on a fragile ecosystem – where sustained investment, long development timelines and high failure rates require policy

Intellectual property is the backbone of the biopharma industry’s innovation ecosystem, driving the discovery and development of life‑saving treatments for patients. In recent years, We Work For Health has presented the Healthcare Innovation Leadership Award to policymakers who demonstrate a sustained commitment to protecting the intellectual property framework that fuels medical innovation. The latest honorees are Representatives Brad Knott (R-NC) and Scott Fitzgerald (R

On April 23, We Work For Health hosted a webinar to examine how a Most Favored Nation pricing policy could affect patient access, affordability, and medical innovation, and why the promised savings may not materialize. Drawing on real‑world examples from Europe and other OECD countries, panelists discussed the unintended but very real consequences of implementing and codifying an MFN policy, including reduced access to lifesaving medicines and limited or nonexistent price rel

Last week, We Work For Health Executive Director Dan Leonard participated in a panel at the HealthCare Institute of New Jersey's (HINJ) 2026 Pulse: Saving Lives Globally, Driving Our Economy Locally – a seminar designed to inform industry leaders, policymakers, and stakeholders about the state of New Jersey's life sciences sector and its leading role in advancing global health. The event took place at Middlesex College in Edison, New Jersey. New Jersey Governor Mikie Sherrill

Together with the Council for Innovation Promotion, We Work For Health recently hosted a roundtable discussion focused on the pivotal role intellectual property plays in advancing innovation, economic growth and patient care across North Carolina. Featured speakers included Congresswoman Deborah Ross (NC-2), along with leading voices in life sciences innovation, including: Dan Leonard, Executive Director, We Work For Health Frank Cullen, Executive Director, Council for Innova

We Work For Health recently hosted a Congressional briefing about the IRA "pill penalty" and the importance of passing the Ensuring Pathways to Innovative Cures (EPIC) Act. Watch the full recording here:

The Drug Price Competition and Patent Term Restoration Act, more commonly known as the Hatch-Waxman Act, profoundly changed the prescription drug landscape. Congress enacted the law in 1984 to create a path to bring generic medicines more easily to market while continuing to incentivize biopharmaceutical innovation. Forty years later, We Work For Health organized an event on Capitol Hill to recognize the landmark bipartisan achievement. Leading policymakers and policy influ

During a recent We Work For Health roundtable with California Rep. Scott Peters, leaders across patient advocacy, biopharma, labor, business and other related fields discussed the importance of protecting and promoting health care innovation. Participants covered a number of topics, including the future of biopharmaceutical innovation in California, near-term legislative and regulatory priorities, and challenges the life sciences industry faces in serving patients. The paneli

During an event on Capitol Hill this week, California Rep. Scott Peters highlighted a graphic that clearly illustrates the distorted impact the Inflation Reduction Act (IRA) has levied on small molecule drugs and biologics. Peters explained the IRA currently allows nine years for small molecule drugs to earn market exclusivity before government price setting takes effect. Biologics, meanwhile, are granted 13 years. “I just saw a graph yesterday,” Peters said, referring to

SAN DIEGO – At a We Work For Health roundtable on June 20, the organization and its partners honored Rep. Scott Peters (CA-50) with the Healthcare Leadership Innovation Award. We Work For Health Executive Director Dan Leonard presented Rep. Peters with the award to recognize the Congressman’s support for policies that foster innovation, including increasing NIH funding, protecting the U.S. patent system and advocating for science-based regulations. Leonard delivered remark

We Work For Health recently convened a conversation to explore the impact policy decisions have on the biopharmaceutical industry and opportunities to help inform the Congressional Budget Office as it reviews future legislation. Watch the full discussion here: